Monoclonal antibody ch14.18 interleukin-2 fusion protein

Drug Profile

Monoclonal antibody ch14.18 interleukin-2 fusion protein

Alternative Names: Anti-ganglioside-GD2-antibody-interleukin-2-fusion-protein; APN 301; ch14.18-IL2; EMD 273063; hu14.18-IL2

Latest Information Update: 24 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexigen Pharmaceuticals
  • Developer Apeiron Biologics; Merck KGaA; University of Wisconsin-Madison
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Neuroblastoma

Most Recent Events

  • 11 Jul 2017 The University of Wisconsin plans a phase I trial for Neuroblastoma (In combination with natural killer cells, In infants, In children, In adolescents, In adults) in USA in September 2017 (NCT03209869)
  • 24 Sep 2015 Phase-II development for Malignant melanoma is ongoing in USA
  • 24 Sep 2015 Phase-II development for Neuroblastoma is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top